Trials / Completed
CompletedNCT05160272
Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes
Effects of GABAA Receptor Modulation by AP-325 on Insulin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- The Deutsche Diabetes Forschungsgesellschaft e.V. · Academic / Other
- Sex
- All
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this single-center, prospective, randomized, double-blind, placebo-controlled, 2-arm parallel-group interventional study is to investigate the effect of 4-week treatment with AP-325 on C-peptide release as measure of insulin secretion compared to placebo in type 2 diabetes (T2D) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AP-325 | Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment. |
| DRUG | Placebo matching AP-325 | Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment. |
Timeline
- Start date
- 2022-01-07
- Primary completion
- 2024-12-17
- Completion
- 2024-12-17
- First posted
- 2021-12-16
- Last updated
- 2025-01-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05160272. Inclusion in this directory is not an endorsement.